Funding
Life-Saving
Innovation

Unlocking Medical Breakthroughs

415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. For over 25 years, our team has been providing exceptional entrepreneurs with capital, clinical, scientific and business expertise, as well as market access.

50+

Medical technology companies funded*

25+

Realized exits (trade-sales and IPOs)*

4.3x

Realized multiple on cash invested*

25+

Active investments*

*Includes CardioVentures and 415 Capital fund families

Investment strategy Value creation

Our Investments

Laza Medical

AI-powered cardiovascular robotics and imaging solutions to improve clinical workflows in structural heart and electrophysiology procedures

Supira Medical

Clinical-stage company developing a low-profile, high continuous flow percutaneous ventricular assist device (pVAD) for high-risk PCI and cardiogenic shock patients

R³ Vascular

Clinical-stage company developing a world-class bioresorbable vascular scaffold technology for patients with peripheral vascular disease

Moray Medical

R&D-stage company developing an innovative robotic catheter platform to enable minimally-invasive cardiovascular procedures

CorFlow

Clinical-stage company developing the first system for both accurate detection and targeted therapy of microvascular obstruction (MVO)

Cardiac Success

Clinical-stage company, developing a minimally invasive transcatheter device to repair and reshape the left ventricle in patients with Heart Failure with reduced Ejection Fraction (HFrEF)

Aktiia

Commercial-stage company pioneering new ways to track, analyze and optimize blood pressure control, enabling physicians to deliver more targeted and timely care

Distalmotion

Commercial-stage company pioneering on-demand surgical robotics. The company’s Dexter robotic platform allows hospitals and surgeons to benefit from the best of all worlds in surgical robotics and laparoscopy

TRiCares

Clinical-stage company developing a minimally invasive transcatheter technology to replace the tricuspid valve in patients suffering from Tricuspid Regurgitation (TR)

See all investments

Further information

Clinical Team

Comprised of physicians and clinical specialists, our Clinical Team provides us with proprietary insights into day-to-day clinical practice, ensuring we have a finger on the pulse of medical innovation and patient care.

Find out more

Investment Team

Our Investment Team combines backgrounds in investing, entrepreneurship, biomedical engineering, business development / strategy, medicine and medical device commercialization.